Harnessing the Power of
Nature's DesignsTM
A BBB-penetrant nanoparticle platform delivering potent small molecules directly to the cells and organs where disease begins
TARGETING THE ROOT CAUSE OF MITOCHONDRIAL DISEASE
Adjuvia Therapeutics is a clinical-stage biopharmaceutical company pioneering blood-brain barrier (BBB)-penetrant nanoparticle therapies that address mitochondrial dysfunction, the fundamental biological mechanism driving rare and chronic degenerative diseases
Lead Program: ATI-105
Our lead asset is a proprietary oral nanoparticle formulation of astaxanthin (ASX) — harvested from Haematococcus pluvialis (HP) microalgae using Adjuvia's patented method. The process produces a novel molecular conformation of ASX with superior bioavailability and bioactivity compared to prior existing ASX formulations.
The nanoparticle's architecture enables rapid systemic uptake and transcytosis across the BBB, delivering its therapeutic payload to cells that need it most. Once inside, the molecule inserts into and spans across cell and mitochondrial membranes, as well as participating directly in cell signaling, the precise locations where oxidative stress and cellular damage begin.
Oral delivery
Orally administered, no injections, no infusions, no safety warnings. Designed for patient convenience and long-term compliance.
BBB-penetrant
Reliably crosses the blood-brain barrier, reaching brain and CNS tissues directly.
Multi-organ reach
Demonstrated penetration into all organs tested — including brain, heart, liver, muscle, pancreas, ovaries, and kidneys.
Membrane-spanning
ASX spans the full cell and mitochondrial membrane to provide superior oxidative protection vs. cytosolic-only antioxidants.
Issued IP portfolio
Strong issued and pending intellectual property covering the extraction process, molecular conformation, and formulation.
Scalable platform
One delivery engine applicable to multiple therapeutic payloads and indications — shared development infrastructure.
Platform Scalability
Shared infrastructure
The same nanoparticle delivery system underpins every indication — reducing development risk and cost across the entire pipeline.
Broad organ penetration
Demonstrated reach into brain, heart, muscle, pancreas, and eye among others, enabling expansion into any organ system affected by mitochondrial dysfunction, with no adverse safety findings.
Additional payload potential
The nanoparticle architecture can carry different therapeutic small molecules beyond astaxanthin, including the BBB-penetrating small molecule EGCG program in development.
Disease Areas
One platform. Multiple conditions. Shared solution
Lead Asset: ATI-105
Rare Mitochondrial Diseases
Lead program: Friedreich's Ataxia (FA)
Fast-follow INDs: Leigh Syndrome (LS) and primary mitochondrial diseases.
Fertility
Planned clinical trials to improve reproductive outcomes by restoring mitochondrial health in the cells and organs that drive fertility.
Partnerable Programs
ATI-105: Longevity & Metabolic Health
Addressing the cellular mechanisms of aging, metabolic disease, and cardiovascular decline at their mitochondrial origin and reversing organ degeneration.
ATI-106: Neurodegeneration
Parkinson's and dementia, conditions where oxidative stress and chronic inflammation drive irreversible neuronal loss, exacerbated by buildup of amyloid plaques. ASX in combination with the first-ever BBB-crossing EGCG molecule, the plaque-busting green tea catechin.